

David P Kelsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/545287/publications.pdf>

Version: 2024-02-01

82
papers

6,355
citations

94269

37
h-index

74018

75
g-index

85
all docs

85
docs citations

85
times ranked

7295
citing authors

#	ARTICLE	IF	CITATIONS
1	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020, 182, 1044-1061.e18.	13.5	691
2	Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3719-3725.	0.8	489
3	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	3.2	281
4	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation. <i>Journal of Clinical Oncology</i> , 2020, 38, 1378-1388.	0.8	265
5	Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 3270-3275.	0.8	246
6	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 821-831.	5.1	243
7	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA</i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. <i>Oncologist</i> , 2011, 16, 1397-1402.	1.9	227
8	Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. <i>Cancer</i> , 1985, 55, 527-534.	2.0	217
9	Cancer of the esophagus and esophagogastric junction—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 304-317.	157.7	212
10	Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 1985-1992.	0.8	198
11	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1067-1074.	3.0	170
12	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015, 121, 4382-4388.	2.0	167
13	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 151, 278-287.e6.	0.6	147
14	Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma assessment of activity and toxicity. <i>Cancer</i> , 1990, 66, 2470-2475.	2.0	136
15	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clinical Cancer Research</i> , 2020, 26, 3239-3247.	3.2	135
16	Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. <i>Cancer</i> , 1994, 73, 273-280.	2.0	125
17	Phase II trial of veliparib in patients with previously treated <i>BRCA</i> -mutated pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 89, 19-26.	1.3	125
18	The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. <i>Cancer</i> , 1993, 71, 3486-3492.	2.0	104

#	ARTICLE	IF	CITATIONS
19	Radiation-induced angiosarcoma. <i>Cancer</i> , 1987, 60, 777-779.	2.0	102
20	Targeted cytogenetic analysis of gastric tumors by in situ hybridization with a set of chromosome-specific dna probes. <i>Cancer</i> , 1990, 66, 491-497.	2.0	94
21	Small cell carcinoma of the esophagus. The memorial hospital experience 1970 to 1987. <i>Cancer</i> , 1989, 64, 1531-1533.	2.0	91
22	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline <i>BRCA</i> mutation carriers and wild-type <i>BRCA</i> pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2018, 124, 1374-1382.	2.0	91
23	Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy. <i>Cancer</i> , 1985, 56, 2512-2518.	2.0	90
24	The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. <i>International Journal of Cancer</i> , 1995, 64, 37-46.	2.3	86
25	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 60, 319-324.	1.8	83
26	A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2001, 91, 101-105.	2.0	80
27	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸ F-(2S,4R)-4-Fluoroglutamine. <i>Radiology</i> , 2018, 287, 667-675.	3.6	80
28	A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. <i>Cancer</i> , 1991, 68, 965-969.	2.0	79
29	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6160-6169.	3.2	73
30	Pharmacokinetics of gallium nitrate in man. <i>Cancer</i> , 1980, 46, 2009-2013.	2.0	72
31	A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. <i>Cancer</i> , 1990, 66, 659-663.	2.0	72
32	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 697-702.	2.9	70
33	A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. <i>Cancer</i> , 1994, 74, 958-961.	2.0	64
34	Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 389-396.	1.1	55
35	Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer. <i>Nature Communications</i> , 2020, 11, 6245.	5.8	51
36	30 Gy may be an adequate dose in patients with anal cancer treated with excisional biopsy followed by combined-modality therapy. , 1999, 70, 71-77.		45

#	ARTICLE	IF	CITATIONS
37	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2020, 126, 3939-3949.	2.0	44
38	A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. <i>Cancer</i> , 1994, 74, 2224-2233.	2.0	41
39	The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. <i>Gastric Cancer</i> , 2018, 21, 1-9.	2.7	41
40	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1-13.	1.4	39
41	Neoadjuvant chemotherapy and surgery of cancer of the esophagus. <i>Journal of Surgical Oncology</i> , 1990, 6, 268-273.	1.4	35
42	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1194-1202.	3.0	35
43	Defining the invasive phenotype of proximal gastric cancer cells. <i>Cancer</i> , 1994, 73, 22-27.	2.0	32
44	Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers. <i>IScience</i> , 2020, 23, 101844.	1.9	31
45	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. <i>Cancer</i> , 2016, 122, 2083-2090.	2.0	30
46	9-aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. , 1997, 80, 1727-1732.		29
47	A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma. <i>Cancer Investigation</i> , 1999, 17, 195-200.	0.6	29
48	A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. <i>Cancer</i> , 1995, 75, 2197-2202.	2.0	28
49	Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer. <i>Cancer</i> , 1983, 51, 1050-1055.	2.0	26
50	Phase II trial of gemcitabine in patients with advanced gastric cancer. <i>Cancer</i> , 1994, 73, 5-7.	2.0	25
51	Pancreas cancer and <i>BRCA1</i> : A critical subset of patients with improving therapeutic outcomes. <i>Cancer</i> , 2021, 127, 4393-4402.	2.0	24
52	Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2015, 14, 269-276.e1.	1.0	23
53	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1429-1437.	3.2	23
54	Neoadjuvant chemotherapy and surgery of cancer of the esophagus. <i>Journal of Surgical Oncology</i> , 1986, 2, 170-176.	1.4	21

#	ARTICLE	IF	CITATIONS
55	ADJUVANT TREATMENT OF COLORECTAL CANCER. Annual Review of Medicine, 1997, 48, 191-202.	5.0	21
56	Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nature Communications, 2022, 13, 2800.	5.8	21
57	Induction and characterization of pancreatic cancer in a transgenic pig model. PLoS ONE, 2020, 15, e0239391.	1.1	19
58	Efficacy of Postoperative 5-FU, High-Dose Leucovorin, and Sequential Radiation Therapy for Clinically Resectable Rectal Cancer. Cancer Investigation, 1995, 13, 1-7.	0.6	16
59	Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. Journal of Thoracic Oncology, 2019, 14, 540-546.	0.5	15
60	Extracellular vesicle and particle isolation from human and murine cell lines, tissues, and bodily fluids. STAR Protocols, 2021, 2, 100225.	0.5	15
61	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	2.8	15
62	A phase I trial of intrahepatic Verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. Cancer, 1994, 74, 2757-2764.	2.0	12
63	Phase II clinical trial of 13-cis-retinoic acid and interferon- γ 2a in patients with advanced esophageal carcinoma. , 1999, 85, 1213-1217.		12
64	Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. Journal of Gastrointestinal Oncology, 2016, 7, 506-514.	0.6	12
65	Multimodality Therapy of Local Regional Esophageal Cancer. Seminars in Oncology, 2005, 32, 6-10.	0.8	11
66	Efficacy of Combined VEGFR1-3, PDGFR α/β , and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	3.2	10
67	A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. Cancer, 1992, 70, 1988-1992.	2.0	9
68	A phase I trial of a modified, dose intensive FAMTX regimen (High dose 5-fluorouracil + doxorubicin + Tj ETQq0 0 0 rgBT /Overlock 10 T		
69	Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. Investigational New Drugs, 1988, 6, 239-41.	1.2	8
70	Pilot study of rapid MR pancreas screening for patients with BRCA mutation. European Radiology, 2019, 29, 3976-3985.	2.3	8
71	A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies. Cancer, 1990, 66, 1688-1691.	2.0	6
72	Prognostic significance of "inflamed" gene expression profile and PD-L1 expression in patients with esophageal cancer. Cancer Medicine, 2021, 10, 8365-8376.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Conformation-Specific Inhibitory Anti-MMP-7 Monoclonal Antibody Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Chemotherapeutic Cell Kill. <i>Cancers</i> , 2021, 13, 1679.	1.7	4
74	Acute toxicity of neoadjuvant bolus 5-FU/methotrexate and leucovorin rescue followed by continuous infusion 5-FU plus pre-operative radiation therapy for rectal cancer. <i>Radiation Oncology Investigations</i> , 1996, 4, 90-97.	1.3	3
75	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. , 2002, 9, 954.		3
76	Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. <i>Cancer</i> , 2022, 128, 2958-2966.	2.0	2
77	Author reply. , 2000, 88, 2426-2426.		1
78	Reply to N. Fazio. <i>Journal of Clinical Oncology</i> , 2020, 38, 2467-2468.	0.8	1
79	Liver-directed conversion therapy in metastatic colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 322-8.	0.6	1
80	Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 255-265.	1.1	1
81	Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract. <i>Investigational New Drugs</i> , 1990, 8, 71-5.	1.2	0
82	S-1 adjuvant chemotherapy for advanced gastric cancer. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 370-371.	4.3	0